Results from the gynecological cohort in a phase 1/2 study (KEYNOTE-B59): endometrial and cervical cancer patients responded to novel immunocytokine GI-101.
- Published in:
- Journal of Gynecologic Oncology, 2024, v. 35, p. 26, doi. 10.3802/jgo.2024.35.S2.P11
- By:
- Publication type:
- Article